当前位置: 首页 >> 检索结果
共有 10907 条符合本次的查询结果, 用时 8.5431927 秒

221. Guideline recommends buprenorphine or methadone as first-line treatment for opioid use disorder (high certainty).

作者: Scott Selinger.; .
来源: Ann Intern Med. 2025年178卷3期JC26页
GIM/FP/GP: [Formula: see text] Public Health: [Formula: see text].

222. In OHCA, IO-first and IV-first vascular access strategies for drug administration did not differ for 30-d survival.

作者: Sheldon Cheskes.; .
来源: Ann Intern Med. 2025年178卷3期JC30页
Emergency Med: [Formula: see text] Cardiology: [Formula: see text].

223. In OHCA, IO-first and IV-first vascular access strategies did not differ for sustained ROSC or 30-d survival.

作者: Sheldon Cheskes.; .
来源: Ann Intern Med. 2025年178卷3期JC31页
Emergency Med: [Formula: see text].

224. In acute MI and acute or chronic anemia, liberal vs. restrictive transfusion did not affect recurrent MI or death.

作者: Julianah O Oguntala.;Andrew T Yan.; .
来源: Ann Intern Med. 2025年178卷3期JC35页
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Hematology: [Formula: see text].

225. In hospitalized patients with BSI, antibiotic therapy for 7 d was noninferior to 14 d for 90-d mortality.

作者: Jonathan H Ryder.;Andre C Kalil.; .
来源: Ann Intern Med. 2025年178卷3期JC27页
GIM/FP/GP: [Formula: see text] Infectious Disease: [Formula: see text] Critical Care: [Formula: see text].

226. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.

作者: Huilin Tang.;Ying Lu.;William T Donahoo.;Sarah C Westen.;Yong Chen.;Jiang Bian.;Jingchuan Guo.
来源: Ann Intern Med. 2025年178卷3期315-326页
Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential antidepressant effects, population studies yield inconsistent results.

227. Development of Prompt Templates for Large Language Model-Driven Screening in Systematic Reviews.

作者: Christian Cao.;Jason Sang.;Rohit Arora.;David Chen.;Robert Kloosterman.;Matthew Cecere.;Jaswanth Gorla.;Richard Saleh.;Ian Drennan.;Bijan Teja.;Michael Fehlings.;Paul Ronksley.;Alexander A Leung.;Dany E Weisz.;Harriet Ware.;Mairead Whelan.;David B Emerson.;Rahul K Arora.;Niklas Bobrovitz.
来源: Ann Intern Med. 2025年178卷3期389-401页
Systematic reviews (SRs) are hindered by the initial rigorous article screen, which delays access to reliable information synthesis.

228. Prevalence of Chronic Medical Conditions Among Medicare Advantage and Traditional Medicare Beneficiaries.

作者: Andrew S Oseran.;Rahul Aggarwal.;Jose Figueroa.;Karen E Joynt Maddox.;Bruce E Landon.;Rishi K Wadhera.
来源: Ann Intern Med. 2025年178卷3期327-335页
The federal government spends billions of dollars per year on payments to Medicare Advantage (MA) plans based, in part, on beneficiaries' risk scores. Despite this, little is known about the true burden of chronic medical conditions among MA beneficiaries compared with those in fee-for-service (FFS) Medicare.

229. De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome : A Systematic Review and Individual Patient Data Meta-analysis of Randomized Clinical Trials.

作者: Yong-Joon Lee.;Xiaofei Gao.;Sang-Hyup Lee.;Jing Kan.;Jun-Jie Zhang.;Seung-Jun Lee.;Sung-Jin Hong.;Chul-Min Ahn.;Jung-Sun Kim.;Byeong-Keuk Kim.;Young-Guk Ko.;Donghoon Choi.;Yangsoo Jang.;Gregg W Stone.;Shao-Liang Chen.;Myeong-Ki Hong.
来源: Ann Intern Med. 2025年178卷4期533-542页
The role of transitioning from short dual antiplatelet therapy (DAPT) to potent P2Y12 inhibitor monotherapy in patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation remains inconclusive.

230. The Target Trial Framework for Causal Inference From Observational Data: Why and When Is It Helpful?

作者: Miguel A Hernán.;Issa J Dahabreh.;Barbra A Dickerman.;Sonja A Swanson.
来源: Ann Intern Med. 2025年178卷3期402-407页
When randomized trials are not available to answer a causal question about the comparative effectiveness or safety of interventions, causal inferences are drawn using observational data. A helpful 2-step framework for causal inference from observational data is 1) specifying the protocol of the hypothetical randomized pragmatic trial that would answer the causal question of interest (the target trial), and 2) using the observational data to attempt to emulate that trial. The target trial framework can improve the quality of observational analyses by preventing some common biases. In this article, we discuss the utility and scope of applications of the framework. We clarify that target trial emulation resolves problems related to incorrect design but not those related to data limitations. We also describe some settings in which adopting this approach is advantageous to generate effect estimates that can close the gaps that randomized trials have not filled. In these settings, the target trial framework helps reduce the ambiguity of causal questions.

231. The Effect of Severe Sepsis and Septic Shock Management Bundle (SEP-1) Compliance and Implementation on Mortality Among Patients With Sepsis : A Systematic Review.

作者: James S Ford.;Joseph C Morrison.;May Kyaw.;Meghan Hewlett.;Peggy Tahir.;Sonia Jain.;Shamim Nemati.;Atul Malhotra.;Gabriel Wardi.
来源: Ann Intern Med. 2025年178卷4期543-557页
The Centers for Medicare & Medicaid Services (CMS) Severe Sepsis and Septic Shock Management Bundle (SEP-1) is now included in the Hospital Value-Based Purchasing (VBP) Program.

232. Potential Clinical and Economic Impacts of Cutbacks in the President's Emergency Plan for AIDS Relief Program in South Africa : A Modeling Analysis.

作者: Aditya R Gandhi.;Linda-Gail Bekker.;A David Paltiel.;Emily P Hyle.;Andrea L Ciaranello.;Yogan Pillay.;Kenneth A Freedberg.;Anne M Neilan.
来源: Ann Intern Med. 2025年178卷4期457-467页
Future U.S. congressional funding for the President's Emergency Plan for AIDS Relief (PEPFAR) program is uncertain.

233. Hemochromatosis.

作者: William C Palmer.;Fernando F Stancampiano.
来源: Ann Intern Med. 2025年178卷2期ITC17-ITC32页
Hemochromatosis is an inheritable condition that mainly affects White populations of European descent. Most patients remain asymptomatic, but others develop advanced organ damage that reduces quality of life and long-term survival. Arthropathy, diabetes mellitus, cirrhosis, hypogonadotropic hypogonadism, and cardiomyopathy are key clinical manifestations. Primary care and hospital medicine physicians play an essential role in early identification of this disease, which can be accomplished via standard hematologic testing. Early diagnosis and therapeutic phlebotomy improve clinical outcomes.

234. Bleeding Risks With Non-Vitamin K Oral Anticoagulants Versus Single Antiplatelet Therapy : A Systematic Review and Meta-analysis of Randomized Trials.

作者: Michael Ke Wang.;Geethan Baskaran.;Ghazal Razeghi.;Richard Ma.;Louis S Park.;Manasi Tannu.;P J Devereaux.;William F McIntyre.;Jeff S Healey.;Ashkan Shoamanesh.;David Conen.
来源: Ann Intern Med. 2025年178卷3期360-368页
In several settings, therapeutic-dose non-vitamin K oral anticoagulants (NOACs) are superior to aspirin for the prevention of arterial and venous thromboembolism.

235. How Would You Manage This Patient With Recent-Onset Atrial Fibrillation? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

作者: Gerald W Smetana.;Eli V Gelfand.;Patricia Tung.;Risa B Burns.
来源: Ann Intern Med. 2025年178卷2期269-278页
Atrial fibrillation (AF) is the most common arrhythmia. Risk factors for AF include obstructive sleep apnea, physical inactivity, obesity, cigarette use, and alcohol misuse. Atrial fibrillation substantially increases the risk for stroke and is associated with higher rates of mortality than for individuals without AF. Strategies to prevent these risk factors and to optimize those that already exist reduce the risk for subsequent AF. Physicians play an important role in proposing strategies to reduce the risk for AF among patients. Decision making regarding management of AF is often complex and requires consideration of symptoms, burden of AF (the percentage of time in AF), comorbid conditions that increase stroke risk, and the risk for bleeding. In particular, novel risk scoring systems to predict stroke risk, and consideration of factors beyond those in these tools, refine the ability to identify patients with AF who are most likely to benefit from anticoagulation to reduce stroke risk. Early use of catheter ablation of AF in selected patients improves symptoms and reduces the potential for progression from intermittent to persistent AF. A 2023 collaborative guideline from the American College of Cardiology, American Heart Association, American College of Chest Physicians, and the Heart Rhythm Society addressed multiple aspects of care of patients with AF. Here, a general cardiologist and a cardiac electrophysiologist discuss recommendations derived from this guideline and how to apply them to the care of a particular patient.

236. Effectiveness and Cost-Effectiveness of Expanded Targeted Testing and Treatment of Latent Tuberculosis Infection Among the Medicare Population in 2022.

作者: Yunfei Li.;Suzanne M Marks.;Garrett R Beeler Asay.;Carla A Winston.;Dawn Pepin.;Susan McClure.;Nicole A Swartwood.;Ted Cohen.;C Robert Horsburgh.;Joshua A Salomon.;Nicolas A Menzies.
来源: Ann Intern Med. 2025年178卷4期479-489页
In the United States, older adults have elevated prevalence of latent tuberculosis infection (LTBI) and incidence of tuberculosis (TB).

237. Assessment and Management of Patients at Risk for Suicide: Synopsis of the 2024 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines.

作者: Lisa A Brenner.;Vince Capaldi.;Joseph Constans.;Steven Dobscha.;Matthew Fuller.;Bridget Matarazzo.;Kate McGraw.;Kenneth Richter.;James Sall.;Derek Smolenski.;Scott Williams.;Sarah Davis-Arnold.;Nazanin Bahraini.
来源: Ann Intern Med. 2025年178卷3期416-425页
The U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DOD) updated the 2019 joint clinical practice guideline (CPG) for assessing and managing patients who are at risk for suicide. This synopsis provides primary care physicians with a summary of the updated 2024 recommendations regarding evaluation and management of military members and veterans at risk for suicide.

238. Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation.

作者: George N Ioannou.;Kristin Berry.;Nallakkandi Rajeevan.;Yuli Li.;Lei Yan.;Yuan Huang.;Hung-Mo Lin.;David Bui.;Denise M Hynes.;Mazhgan Rowneki.;Amy Bohnert.;Edward J Boyko.;Theodore J Iwashyna.;Matthew L Maciejewski.;Valerie A Smith.;Theodore S Z Berkowitz.;Ann M O'Hare.;Elizabeth M Viglianti.;Mihaela Aslan.;Kristina L Bajema.
来源: Ann Intern Med. 2025年178卷3期348-359页
Monovalent COVID-19 vaccines targeting the XBB.1.5 Omicron variant were introduced in September 2023. In the absence of randomized controlled trials demonstrating their efficacy, information on real-world vaccine effectiveness (VE) is needed.

239. In acute ischemic stroke with AF, early DOAC initiation was noninferior to delayed initiation for ischemic and hemorrhagic outcomes at 90 d.

作者: Mukul Sharma.;Abhilekh Srivastava.; .
来源: Ann Intern Med. 2025年178卷2期JC16页
GIM/FP/GP: [Formula: see text] Neurology: [Formula: see text] Hematology: [Formula: see text].

240. In arterial hypertension, renal denervation vs. a sham procedure reduces ambulatory and office BP at ≤6 mo.

作者: Swapnil Hiremath.; .
来源: Ann Intern Med. 2025年178卷2期JC17页
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Nephrology: [Formula: see text].
共有 10907 条符合本次的查询结果, 用时 8.5431927 秒